SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it has completed its business combination with CM Life Sciences II, Inc. (Nasdaq: CMIIU), a special purpose acquisition company sponsored by affiliates of leading healthcare and life sciences fund advisors Casdin Capital and Corvex Management. Following the transaction, the combined company was renamed SomaLogic, Inc., and its Class A common stock and warrants will begin trading on the Nasdaq Global Market (“Nasdaq”) on September 2, 2021 under the symbols “SLGC” and “SLGCW,” respectively. The business combination and concurrent private placement were approved by CM Life Sciences II shareholders at its special meeting held on August 31st, 2021.SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it has completed its business combination with CM Life Sciences II, Inc. (Nasdaq: CMIIU), a special purpose acquisition company sponsored by affiliates of leading healthcare and life sciences fund advisors Casdin Capital and Corvex Management. Following the transaction, the combined company was renamed SomaLogic, Inc., and its Class A common stock and warrants will begin trading on the Nasdaq Global Market (“Nasdaq”) on September 2, 2021 under the symbols “SLGC” and “SLGCW,” respectively. The business combination and concurrent private placement were approved by CM Life Sciences II shareholders at its special meeting held on August 31st, 2021.
Read Full Release
Pharmaceutical researchers are turning to technology to broaden access to experimental treatments, and make clinical trials more equitable in terms of their inclusion of minorities
Minorities are often underrepresented as participants in studies of new drugs—leaving them with less access to new, potentially lifesaving drugs, and making scientists less aware of how medicines affect people of various races differently. One reason is minority groups, because of abuses in the past, sometimes distrust the medical system. Minorities also can lack the resources needed to travel or fulfill other requirements to be able to participate in drug trials.
Read Full Release
Clinical Research IO (CRIO), a Boston-based technology firm offering clinical research sponsors and sites a platform to streamline clinical trials, announced the completion of a $3.5 million Series A round led by Rally Ventures.
The round allows CRIO to expand its product and engineering teams to develop the next wave of products. "Our goal has always been to streamline clinical research," said Raymond Nomizu, company co-founder and CEO. "To do this, we need to ramp up our product and engineering teams. We have laid the groundwork with our unparalleled site network of electronic adopters, and now we want to leverage this to unlock efficiencies for sponsors and contract research organizations (CROs)."
Read Full Release
medaptus today announced that its professional charge capture and charge reconciliation solution, Charge Pro, has again achieved the #1 Mobile Charge Capture ranking in the annual "Best in KLAS: Software & Services" report. medaptus has earned this distinction for the past eleven out of 12 years.
For the 2021 report, the company's top-ranking score of 94.7 is based on customer feedback obtained in the year 2020 across measures such as product quality, value, and support. Charge Pro customers, some of which have been working with company for nearly 20 years, include single-specialty practices, hospital medicine teams, and larger provider entities such as IDNs. More complex entities often rely on medaptus for its unparalleled integration capabilities in order to normalize disparate data sources for full revenue cycle transparency.
Read Full Release
Cecelia Health, a leading virtual health company that empowers people with diabetes and chronic conditions to live better and healthier lives, today announced that it has appointed industry veteran Mark Clermont to succeed founder David Weingard as Cecelia’s Chief Executive Officer. Clermont’s demonstrated leadership and healthcare expertise will help Cecelia Health accelerate and further scale adoption of the company's technology-enabled expert clinical, digital telehealth, and telemedicine solutions. Weingard will transition to his new role as Executive Chairman of the Board where he will continue to support the company on corporate strategy, brand awareness and developing long-term executive relationships.
Read Full Release
LifeScan, a world leader in blood glucose monitoring, serving 20 million people with diabetes and the maker of the iconic OneTouch® brand products, and Cecelia Health, one of the nation's most scalable clinical coaching and telehealth companies focused on diabetes and other chronic disease management, today announced a partnership to deliver best-in-class, live, personalized coaching from Cecelia Health's Certified Diabetes Care and Education Specialists through our OneTouch Reveal app beginning November 2020.
Read Full Release
Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal.
The Beat AML trial achieved its primary endpoint by showing genomic analysis of the leukemia cells to identify AML subtypes can be completed within an unprecedented seven days, giving patients, caregivers and their doctors ample time to make a more personalized treatment decision without risking the patient’s chance for survival.
Read Full Release
Migraine and cataract therapies and a transit solution for vaccines such as Covid-19 are among the new cutting-edge innovations to be presented in the virtual 30th MedTech Investing Europe Conference on 21-22 October, 2020.
Campden Wealth organisers said attendees will be able to participate online and benefit from everything the MedTech Investing events normally offered—industry leading content, speakers from some of the world’s foremost investors and dedicated networking for both investors and presenting companies. Attendees were required to pre-register and will receive full details, access links and schedule in advance of the event.
Read Full Release
Three tech startups from various parts of the Garden State competed in a Startup Showdown last week that focused on real-world data and evidence collection.
The Startup Showdowns are presented by TechUnited:NJ (New Brunswick) and Tech Council Ventures (Summit) and hosted by Jasmine Hoffman.
Pitching were Daniel Ferrara, founder and CEO of Roseland-based WellCare Today; Luke Malanga, COO of Cedar Knolls-based DataBiologics; and Kirsten Hund Blair, cofounder and CEO of Princeton-based Lambent Data.
The investors who gave feedback were: Mark Kolb, entrepreneur in residence, Tech Council Ventures, who focuses on the healthcare industry; Steven Cohen, partner, Morgan Lewis (Philadelphia), who is chair of the Morgan Lewis emerging business and technology practice and an angel investor; and Ren Roome, principal, Boston Millennia Partners.
The complete video of the program can be found here.
For this episode, Lambent Data took home the audience choice award.
Read Full Release
The Evolving Relationship Between Real World Data and Clinical Trials with Nancy Dreyer and C.K. Wang
In this episode of Real World Talk, host Zoe Li talks to Nancy Dreyer, Chief Scientific Officer of IQVIA, and COTA’s own Chief Medical Officer, Dr. C.K. Wang.
They discuss the interactions between real world data and clinical trials, and how the two approaches can complement each other. They also look at why the Lancet retracted a large study into the use of hydroxychloroquine to treat COVID-19 in June, after questions were raised about its curation and application of real world data.
Read Full Release
